stockrow
Saturday 7 November 2026
Export VIVS’s income statement to Excel — free account
VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025.
- Revenue
- −51.4%
- EPS
- +78.1%
- Free cash flow
- +17.9%
Quarter to June 2026, against a year earlier
0.14
0.00
0.00%
Follow VIVS
Alert me
VivoSim Labs, Inc. (VIVS) P/E ratio
VivoSim Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5.5× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 1.0× | (79.33%) |
| Sep 2025 | 4.7× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5.5×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| VIVS VivoSim Labs, Inc. | n/m |
| EOCN Eocene Ltd. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)